|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Allogene Therapeutics, Inc. (ALLO) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
140,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic Chimeric antigen receptor (CAR) T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. Co. is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma, and other blood cancers and solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,724,137 |
1,724,327 |
1,724,327 |
1,724,327 |
| Total Buy Value |
$4,999,997 |
$5,000,680 |
$5,000,680 |
$5,000,680 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
18,640 |
28,640 |
71,242 |
| Total Sell Value |
$0 |
$50,317 |
$93,172 |
$615,058 |
| Total People Sold |
0 |
1 |
2 |
5 |
| Total Sell Transactions |
0 |
1 |
2 |
11 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kazam Joshoa A |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
44,178 |
303,063 |
|
- |
|
| Sato Vicki L |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,089 |
41,451 |
|
- |
|
| Witte Owen N. |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,089 |
243,271 |
|
- |
|
| Humer Franz B |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
44,178 |
191,892 |
|
- |
|
| Amado Rafael |
EVP of R&D and CMO |
• – – |
2022-05-19 |
4 |
S |
$7.40 |
$85,092 |
D/D |
(11,500) |
546,257 |
|
- |
|
| Pf Equity Holdings 2 B.v. |
10% Owner |
– – • |
2022-03-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(22,032,040) |
0 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2022-03-23 |
4 |
A |
$0.00 |
$0 |
D/D |
175,438 |
589,279 |
|
- |
|
| Schmidt Eric Thomas |
Chief Financial Officer |
• – – |
2022-03-23 |
4 |
A |
$0.00 |
$0 |
D/D |
237,358 |
337,904 |
|
- |
|
| Amado Rafael |
EVP of R&D and CMO |
• – – |
2022-03-23 |
4 |
A |
$0.00 |
$0 |
D/D |
237,358 |
557,477 |
|
- |
|
| Chang David D |
President and CEO |
• • – |
2022-03-15 |
4 |
S |
$7.65 |
$180,879 |
D/D |
(23,648) |
2,289,652 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2022-03-15 |
4 |
S |
$7.68 |
$67,962 |
D/D |
(8,849) |
413,841 |
|
- |
|
| Amado Rafael |
EVP of R&D and CMO |
• – – |
2022-03-15 |
4 |
S |
$7.71 |
$39,848 |
D/D |
(5,169) |
320,119 |
|
- |
|
| Schmidt Eric Thomas |
Chief Financial Officer |
• – – |
2022-03-15 |
4 |
S |
$7.63 |
$87,551 |
D/D |
(11,469) |
100,546 |
|
- |
|
| Moore Alison |
Chief Technical Officer |
• – – |
2022-03-15 |
4 |
S |
$7.63 |
$66,388 |
D/D |
(8,698) |
120,430 |
|
- |
|
| Belldegrun Arie |
|
– • – |
2022-03-14 |
4/A |
A |
$0.00 |
$0 |
I/I |
4,710,120 |
4,710,120 |
|
- |
|
| Belldegrun Arie |
|
– • – |
2022-03-14 |
4/A |
D |
$0.00 |
$0 |
I/I |
(4,710,120) |
0 |
|
- |
|
| Belldegrun Arie |
|
– • – |
2022-03-14 |
4 |
A |
$0.00 |
$0 |
I/I |
4,710,121 |
4,710,121 |
|
- |
|
| Belldegrun Arie |
|
– • – |
2022-03-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,710,121) |
0 |
|
- |
|
| Kazam Joshoa A |
|
– • – |
2022-03-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
412,618 |
258,885 |
|
- |
|
| Kazam Joshoa A |
|
– • – |
2022-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
412,618 |
671,503 |
|
- |
|
| Belldegrun Arie |
|
– • – |
2022-01-12 |
4 |
B |
$12.60 |
$1,953,491 |
I/I |
155,039 |
195,039 |
0.01 |
- |
|
| Kazam Joshoa A |
|
– • – |
2022-01-12 |
4 |
B |
$12.60 |
$189,000 |
D/D |
15,000 |
258,885 |
0.01 |
- |
|
| Amado Rafael |
EVP of R&D and CMO |
• – – |
2021-10-01 |
4 |
S |
$24.35 |
$280,185 |
D/D |
(11,507) |
323,928 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2021-09-15 |
4 |
AS |
$24.77 |
$123,845 |
D/D |
(5,000) |
421,669 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2021-09-15 |
4 |
OE |
$2.27 |
$11,350 |
D/D |
5,000 |
426,669 |
|
- |
|
225 Records found
|
|
Page 3 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
